About Biohaven Ltd.
https://www.biohaven.comBiohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
CEO
Vladimir Coric
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
Citigroup
Buy
TD Cowen
Buy
B of A Securities
Buy
Baird
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:7.87M
Value:$92.14M
JANUS HENDERSON GROUP PLC
Shares:6.77M
Value:$79.23M
STIFEL FINANCIAL CORP
Shares:6.61M
Value:$77.35M
Summary
Showing Top 3 of 332
About Biohaven Ltd.
https://www.biohaven.comBiohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $168.28M ▼ | $-173.44M ▲ | 0% | $-1.64 ▲ | $-172.12M ▲ |
| Q2-2025 | $0 | $211.7M ▼ | $-198.15M ▲ | 0% | $-1.94 ▲ | $-209.72M ▲ |
| Q1-2025 | $0 | $221.56M ▲ | $-221.68M ▼ | 0% | $-2.17 ▼ | $-219.31M ▼ |
| Q4-2024 | $0 | $189.93M ▲ | $-186.84M ▼ | 0% | $-1.85 ▼ | $-187.47M ▼ |
| Q3-2024 | $0 | $178.17M | $-160.3M | 0% | $-1.7 | $-176.17M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $260.22M ▼ | $409.12M ▼ | $426.28M ▲ | $-17.16M ▼ |
| Q2-2025 | $404.98M ▲ | $550.41M ▲ | $415.83M ▲ | $134.59M ▼ |
| Q1-2025 | $322.75M ▼ | $458.95M ▼ | $199.45M ▲ | $259.5M ▼ |
| Q4-2024 | $485.99M ▲ | $615.11M ▲ | $191.67M ▼ | $423.44M ▲ |
| Q3-2024 | $378.82M | $510.52M | $194.52M | $316.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-173.44M ▲ | $-145.72M ▲ | $164.97M ▲ | $122K ▼ | $19.39M ▼ | $-145.73M ▲ |
| Q2-2025 | $-198.15M ▲ | $-167.94M ▼ | $-15.55M ▼ | $249.83M ▲ | $66.31M ▲ | $-168.17M ▼ |
| Q1-2025 | $-221.68M ▼ | $-165.12M ▲ | $164.88M ▲ | $369K ▼ | $147K ▼ | $-165.59M ▲ |
| Q4-2024 | $-186.84M ▼ | $-170.74M ▼ | $-87.68M ▲ | $272.85M ▲ | $14.52M ▲ | $-170.79M ▼ |
| Q3-2024 | $-160.3M | $-141.28M | $-93.4M | $80.38M | $-154.3M | $-141.89M |
CEO
Vladimir Coric
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
Citigroup
Buy
TD Cowen
Buy
B of A Securities
Buy
Baird
Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:7.87M
Value:$92.14M
JANUS HENDERSON GROUP PLC
Shares:6.77M
Value:$79.23M
STIFEL FINANCIAL CORP
Shares:6.61M
Value:$77.35M
Summary
Showing Top 3 of 332